SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 16823.
  • 2
    Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 35166.
  • 3
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 173345.
  • 4
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 1536.
  • 5
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 6
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 67886.
  • 7
    De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 (Suppl. 1): S325.
  • 8
    Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 1239.
  • 9
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 10
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 11
    Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39 (Suppl. 1): S938.
  • 12
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93: 4398402.
  • 13
    Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 (Suppl. 1): 310.
  • 14
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2’,3’-dideoxy-3’-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88: 84959.
  • 15
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 125663.
  • 16
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 618.
  • 17
    Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 18
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 101120.
  • 19
    Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 127682.
  • 20
    Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 21
    Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 17280.
  • 22
    Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 152732.
  • 23
    Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001; 16 (Suppl. 1): A601.
  • 24
    Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 74855.
  • 25
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32 (4 Pt 1): 8036.
  • 26
    Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39: 6149.
  • 27
    Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003; 52: 177983.
  • 28
    Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 25762.
  • 29
    Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 68796.
  • 30
    Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 10517.
  • 31
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 56772.
  • 32
    Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 33
    De Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29: 66975.
  • 34
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32 (4 Pt 1): 84751.
  • 35
    Gaia S, Marzano A, Smedile A, et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004; 20: 2817.
  • 36
    Scotto G, Fazio V, Campanozzi F, D’Adduzio A. Efficacy of treatment with lamivudine in patients with chronic active E-minus variant hepatitis B virus infection: a non-randomized, open label study. Curr Ther Res 2000; 61: 32130.
  • 37
    Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002; 66: 43551.
  • 38
    Shouval D, Lai CL, Cheinquer H, et al. Entacavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027. Hepatology 2004; 40 (4 Suppl. 1): 728A.
  • 39
    Simsek H, Schiff E, Goodman Z, Brett-Smith H, Klesczewski K, Kreter B. Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: results of three pivotal trials. J Hepatol 2006; 44 (Suppl. 2): S191.
  • 40
    Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001; 8: 2705.
  • 41
    Tassopoulos NC, Anagnostopoulos GD. Long-term lamivudine treatment of patients with pre-core mutant profile (HBEAg(-)/Anti-HBe+) chronic hepatitis B. Antivir Ther 2000; 5 (Suppl. 1): 34.
  • 42
    Dimou E, Papatheodoridis GV, Laras A, Hadziyannis SJ Efficacy of long-term lamivudine monotherapy in HBeAg negative chronic hepatitis B. 2000; 5 (Suppl. 1): 44.
  • 43
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 3006.
  • 44
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 88996.
  • 45
    Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005; 42: 1739.
  • 46
    Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 4328.
  • 47
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 48
    Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 11538.
  • 49
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 267381.
  • 50
    Mao YM, Zheng MD, Yao GB, et al. Efficacy and safety of two years therapy with adefovir dipixoxil (ADV) in Chinese subjects with HBeAg positive chronic hepatitis B (CHB). J. Hepatology 2006; 44 (Suppl. 2): S185.
  • 51
    Durantel S, Werle B, Durantel D, et al. Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B. Hepatology 2004; 40 (4 Suppl. 1): 654A.
  • 52
    Marcellini P, Chang TT, Lim SG, et al. Increasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. J Hepatol 2005; 42 (Suppl. 2): 312.
  • 53
    Chang TT, Schiffman ML, Tong M, et al. Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. J Hepatol 2006; 44 (Suppl. 2): S187.
  • 54
    Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol 2006; 5: 1.
  • 55
    Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine-resistant chronic hepatitis B patients treated with ADV. Gut 2006; 55: 148895.
  • 56
    Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 93743.
  • 57
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 58
    Hadziyannis SJ, Tassopoulos NC, Chang TT, et al. Two state modeling of virological and biochemical efficacy plus liver biopsies demonstrate efficacy of adefovir dipivoxil in HBeAg-negative chronic hepatitis B over 4 or 5 years. J. Hepatology 2006; 44 (Suppl. 2): S184.
  • 59
    Hadziyannis SJ, Tassopoulos NC, Chang TT, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology 2005; 42 (4 Suppl. !): 754A.
  • 60
    Gish RG, Chang TT, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology 2005; 42 (4 Suppl. 1): 267A.
  • 61
    Colonno RJ, Rose RE, Baldick CJ, Levine SM, Klesczewski K, Tenney DJ. High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J Hepatol 2006; 44 (Suppl. 2): S182.
  • 62
    Huang ZM, Huang QW, Qin YQ, et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11: 86770.
  • 63
    Schildgen O, Sirma H, Funk A, et al. Primary resistance of a novel hepatitis B virus variant to adefovir. J Hepatol 2006; 44 (Suppl. 2): S190.
  • 64
    Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 7704.
  • 65
    Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 18694.
  • 66
    Villeneuve J, Willems B, Zoulim F. Efficacy of tenofovir in patients with chronic hepatitis B and resistance or sub-optimal response to adefovir. Hepatology 2005; 42 (4 Suppl. 1): 588A.
  • 67
    Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004; 48: 370210.
  • 68
    Ide T, Kumashiro R, Koga Y, et al. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Am J Gastroenterol 2003; 98: 204851.
    Direct Link:
  • 69
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34 (4 Pt 1): 78591.
  • 70
    Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 28390.
  • 71
    Lee CH, Yeon JE, Pyo S, et al. More frequent and earlier emergence of adefovir (ADV) resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleoside-treatment naïve patients. Hepatology 2005; 42 (Suppl. 1): 593A.
  • 72
    Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 (Suppl. 2): 17.
  • 73
    Colonno R, Rose R, Levine S, et al. Entecavir two year resistance update: no resistance observed in nucleotide naïve patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 2005; 42 (Suppl. 1): 573A.
  • 74
    Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 67993.
  • 75
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 122541.
  • 76
    Lok AS, McMahon BJ. AASLD Practice Guidelines Chronic hepatitis B: update of therapeutic guidelines. Rom J Gastroenterol 2004; 13: 1504.
  • 77
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 21926.
  • 78
    Hussain M, Fung S, Libbrecht E, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44: 10947.
  • 79
    Sertoz RY, Erensoy S, Pas S, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 51420.
  • 80
    Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 81
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 82
    Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 14149.
  • 83
    Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21: 5317.
  • 84
    Lee Y, Suh DJ, Lim YS, et al. Emergence of rtA181V/T and rtN236T mutations after 48 weeks of adefovir dipivoxil therapy in patients with lamivudine-resistant chronic hepatitis B. Hepatology 2005; 42 (Suppl. 1): 578A.
  • 85
    Snow A, Thibault V, Qi X, Zhu Y, Westland C, Arterburn S. Combination of adefovir (ADV) and lamivudine (LAM) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBV. Gastroenterology 2005; 128: M945.
  • 86
    Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026. Hepatology 2004; 40 (4 Suppl. 1): 664A.
  • 87
    Yurdaydin C, Sollano J, Hadziyannis SJ, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). J Hepatol 2006; 44 (Suppl. 2): S36.
  • 88
    Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498507.
  • 89
    Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 62533.
  • 90
    Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 14215.
  • 91
    Van Bömmel F, Mauss S, Zollner B, et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir. Hepatology 2005; 42 (4 Suppl. 1): 269A.
  • 92
    Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 13918.
  • 93
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 2927.
  • 94
    Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother 2005; 55: 60811.
  • 95
    Villet V, Pichoud C, Ollivet A, Villeneuve J, Trepo C, Zoulim F. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology 2005; 42 (Suppl. 1): 581A.
  • 96
    Lampertico P, Marzano A, Levrero M, et al. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients. Hepatology 2005; 42 (4 Suppl. 1): 591A.